中国医学创新2024,Vol.21Issue(13) :162-167.DOI:10.3969/j.issn.1674-4985.2024.13.037

滤泡性淋巴瘤的治疗进展

Therapeutic Progress of Follicular Lymphoma

初文慧 高娜 刘增艳 曹曰针 孙大伟 于文征
中国医学创新2024,Vol.21Issue(13) :162-167.DOI:10.3969/j.issn.1674-4985.2024.13.037

滤泡性淋巴瘤的治疗进展

Therapeutic Progress of Follicular Lymphoma

初文慧 1高娜 1刘增艳 1曹曰针 1孙大伟 1于文征1
扫码查看

作者信息

  • 1. 滨州医学院附属医院血液内科 山东 滨州 256603
  • 折叠

摘要

滤泡性淋巴瘤(follicular lymphoma,FL)是最常见的惰性B细胞非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),它是一种异质性疾病,其治疗方式多样,包括观察、放疗和全身治疗.但对于多数患者来说,在找到治疗指征之前观察仍然是最常见的治疗方法.早期FL患者的标准治疗方法是放疗,晚期或复发/难治性FL患者可以选择免疫化疗、靶向免疫治疗等.近年来,随着对FL发病机制的深入研究,新的药物和治疗方法也层出不穷,本文对FL的治疗进展做一综述.

Abstract

Follicular lymphoma(FL)is the most common inert B-cell non-Hodgkin lymphoma(NHL).It is a heterogeneous disease,and its treatment methods are diverse,including observation,radiotherapy and systemic treatment.However,for most patients,observation is still the most common treatment method before finding the indications for treatment.The standard treatment for patients with early-stage FL is radiotherapy,while patients with late-stage or relapsed/refractory FL can choose immunochemotherapy,targeted immunotherapy,etc.In recent years,with the in-depth study of the pathogenesis of FL,new drugs and treatment methods are emerging in an endless stream.This article reviews the therapeutic progress of FL.

关键词

滤泡性淋巴瘤/免疫化疗/靶向免疫治疗

Key words

Follicular lymphoma/Immunochemotherapy/Targeted immunotherapy

引用本文复制引用

出版年

2024
中国医学创新
中国保健协会

中国医学创新

影响因子:1.706
ISSN:1674-4985
参考文献量48
段落导航相关论文